IXICO マネジメント

マネジメント基準チェック /24

IXICOの CEO はBram Goordenで、 Aug2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.57%を直接所有しており、その価値は€ 78.78K 。経営陣と取締役会の平均在任期間はそれぞれ7.3年と4年です。

主要情報

Bram Goorden

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.6%
経営陣の平均在職期間	7.3yrs
取締役会の平均在任期間	4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Bram Goorden (50 yo)

less than a year

在職期間

Mr. Bram Goorden, M.Sc., serves as Chief Executive Officer of IXICO plc since August 19, 2024. He served as Chief Operating Officer and Senior Vice President at SOPHiA GENETICS SA since August 2020 until 2...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Grant Nash	CFO, Company Secretary & Executive Director	5.6yrs	UK£216.00k	0.55% € 75.6k
Bram Goorden	Chief Executive Officer	less than a year	データなし	0.57% € 78.8k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	20.8yrs	データなし	データなし
Derek Lionel Hill	Co-Founder and President of Regulatory Science & External Relations	7.3yrs	UK£387.01k	データなし
David Hawkes	Co-Founder & Member of Scientific Advisory Board	20.8yrs	データなし	データなし
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	20.8yrs	データなし	データなし
Mark Austin	Director of Technology	no data	データなし	データなし
Robin Wolz	Chief Scientific Officer	no data	データなし	データなし
Hannah Esfahanian	HR Manager	no data	データなし	データなし
John Hall	Senior Vice President of Business Development	8.5yrs	データなし	データなし
Lammert Albers	Chief Business Officer	5.1yrs	データなし	データなし
Alison Howie	Chief Product Officer	6.4yrs	データなし	データなし

7.3yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: PYPBの経営陣は経験豊富で経験豊富です（平均在職期間は7.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Grant Nash	CFO, Company Secretary & Executive Director	5.3yrs	UK£216.00k	0.55% € 75.6k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
David Hawkes	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Dipti Amin	Independent Non-Executive Director	1.1yrs	データなし	0.11% € 15.8k
Mark Warne	Independent Non-Executive Chair	8.2yrs	UK£31.00k	0.078% € 10.8k
Katherine Rogers	Senior Independent Non-Executive Director	2.8yrs	UK£31.00k	0.057% € 7.9k

4.0yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: PYPBの取締役会は経験豊富であると考えられます ( 4年の平均在任期間)。

IXICO マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

IXICO plc, Annual General Meeting, Jan 25, 2024

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

IXICO plc, Annual General Meeting, Jan 27, 2023

Recent updates

IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024

New major risk - Share price stability

New major risk - Shareholder dilution

Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

New major risk - Revenue and earnings growth

IXICO plc to Report First Half, 2024 Results on May 21, 2024

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

Full year 2023 earnings released: UK£0.024 loss per share (vs UK£0.021 profit in FY 2022)

IXICO plc, Annual General Meeting, Jan 25, 2024

IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023

New major risk - Market cap size

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

New major risk - Revenue and earnings growth

IXICO plc Provides Earnings Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022)

IXICO plc to Report First Half, 2023 Results on May 23, 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

Full year 2022 earnings released: EPS: UK£0.021 (vs UK£0.033 in FY 2021)

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Financial Year 2023

First half 2022 earnings released

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022

IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020)

Investor sentiment improved over the past week

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited

Investor sentiment improved over the past week

IXICO plc Announces Collaboration with Microsoft

Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial

IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc

New 90-day low: €0.98

IXICO Secures New Contract for £3.4 Million

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS UK£0.02

Revenue beats expectations

IXICO plc, Annual General Meeting, Jan 21, 2021

IXICO plc Announces £1.9 Million New Study Award

Market bids up stock over the past week

New 90-day high: €1.26

Market bids up stock over the past week

IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020

Market bids up stock over the past week

New 90-day high: €1.22

Market bids up stock over the past week

IXICO plc and NYU Langone Health Signs Agreement

IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease

Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance

Global Alzheimer's Platform Foundation Selects IXICO plc for Innovative Bio-Hermes Trial

New 90-day high - €0.94

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24